This is a dataset summarising demographic, hepatitis B test results and alanine aminotransferase data from 6 completed different clinical trials conducted at KEMRI-Wellcome Trust Research Programme since 2016. The aim of this work was to give a seroprevalence estimate for HBV in Kilifi and also illustrate the amount of data that is likely available in this space that is currently underutilised. Data were accessed with permission from study PIs and from sponsors where necessary. These data were standardised for age and sex using the Kilifi health and demographic surveillance system (KHDSS) data as the standard population structure. This data showed a crude HBsAg seroprevalence rate of 3.5%, which rose to 5% when standardised. There was considerable underrepresentation of women in these trials with 77% of participants being male. ALT was significantly higher in those who were HBsAg positive compared to negative, although was not outside the upper limit of normal for this population. We argue from these results that routine collection and collation of both blood borne virus prevalence and liver function test information will enable better modelling of not only blood borne viruses, but also for estimating the burden from liver disease across the African region. This would be a low cost, efficient method that negates the need for the organisation of large sero-epidemiological surveys

Chronic hepatitis B, Clinical trials, Seroprevalence, Elimination Goals, Clinical care